NMOSD
MCID: NRM008
MIFTS: 31

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 52
Neuromyelitis Optica 71
Nmosd 52

Classifications:



External Ids:

UMLS 71 C0027873

Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and myelitis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Prednisone and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and spinal cord.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 31.8 CD27 AQP4
2 myelitis 31.2 CD27 AQP4
3 transverse myelitis 31.0 CD27 AQP4
4 multiple sclerosis 30.4 CD27 AQP4
5 neuritis 11.2
6 optic neuritis 11.2
7 autoimmune disease 10.9
8 demyelinating disease 10.9
9 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
10 relapsing-remitting multiple sclerosis 10.6
11 myasthenia gravis 10.6
12 acute disseminated encephalomyelitis 10.6
13 sjogren syndrome 10.6
14 yemenite deaf-blind hypopigmentation syndrome 10.6
15 encephalitis 10.6
16 ataxia and polyneuropathy, adult-onset 10.5
17 encephalopathy 10.5
18 hypothyroidism 10.5
19 hypersomnia 10.5
20 acute transverse myelitis 10.5
21 systemic lupus erythematosus 10.4
22 lupus erythematosus 10.4
23 pathologic nystagmus 10.4
24 aphasia 10.4
25 dysphagia 10.4
26 kearns-sayre syndrome 10.4
27 pre-eclampsia 10.4
28 neutropenia 10.4
29 adenocarcinoma 10.4
30 central nervous system disease 10.4
31 sleep disorder 10.4
32 paraplegia 10.4
33 chickenpox 10.4
34 pure autonomic failure 10.4
35 scleroderma, familial progressive 10.3
36 lung cancer susceptibility 3 10.3
37 secondary progressive multiple sclerosis 10.3
38 leukodystrophy 10.3
39 interstitial lung disease 10.3
40 movement disease 10.3
41 thyroid gland disease 10.3
42 internuclear ophthalmoplegia 10.3
43 lung disease 10.3
44 nervous system disease 10.3
45 narcolepsy 10.3
46 47,xyy 10.3
47 cytokine deficiency 10.3
48 paresthesia 10.3
49 spasticity 10.3
50 spondyloarthropathy 1 10.2

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
3 Analgesics Phase 4
4 Topoisomerase Inhibitors Phase 4
5
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
6
Azathioprine Approved Phase 3 446-86-6 2265
7 Complement System Proteins Phase 3
8 Complement Inactivating Agents Phase 3
9 Vaccines Phase 3
10 Hormone Antagonists Phase 3
11 glucocorticoids Phase 3
12 Hormones Phase 3
13 Anti-Inflammatory Agents Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
16
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
17
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
18
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
19
Chlorpheniramine Approved Phase 2 113-92-8, 132-22-9 2725
20
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
21
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6 774
22
4-Aminopyridine Approved Phase 2 504-24-5 1727
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 1177-87-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
25 Proteasome Inhibitors Phase 2
26 Hydrocortisone hemisuccinate Phase 2
27 Hydrocortisone 17-butyrate 21-propionate Phase 2
28 Neurotransmitter Agents Phase 1, Phase 2
29
Histamine Phosphate Phase 1, Phase 2 51-74-1 65513
30 Histamine Antagonists Phase 1, Phase 2
31 Histamine H1 Antagonists Phase 1, Phase 2
32 Histamine H1 Antagonists, Non-Sedating Phase 1, Phase 2
33 Anti-Allergic Agents Phase 1, Phase 2
34 Potassium Channel Blockers Phase 2
35 Pharmaceutical Solutions Phase 2
36 BB 1101 Phase 1, Phase 2
37
Bevacizumab Approved, Investigational Phase 1 216974-75-3
38 Angiogenesis Inhibitors Phase 1
39 Complement C1s Phase 1
40 Complement C1 Inhibitor Protein Phase 1
41 Complement C1 Inactivator Proteins Phase 1
42
Mycophenolic acid Approved 24280-93-1 446541
43
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
44 interferons
45 Adjuvants, Immunologic
46 Antiviral Agents
47 Radiation-Protective Agents
48 Interferon Inducers
49 Antimetabolites
50 Anti-Bacterial Agents

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
2 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial Completed NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
6 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
7 Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment Completed NCT01442233 Phase 3
8 A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) Recruiting NCT04201262 Phase 3
9 A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders. Recruiting NCT03330418 Phase 3
10 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Active, not recruiting NCT02073279 Phase 3 Satralizumab;Placebo
11 A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Active, not recruiting NCT02003144 Phase 3
12 A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
13 A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) Active, not recruiting NCT02028884 Phase 3 Satralizumab;Placebo;Baseline Treatment
14 A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder Not yet recruiting NCT04155424 Phase 2, Phase 3 Eculizumab
15 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Terminated NCT01892345 Phase 3 Eculizumab;Placebo
16 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
17 Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD) Withdrawn NCT03829566 Phase 2, Phase 3 Rituximab;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
18 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
19 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
20 Single-center, Open Label Trial of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
21 Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD) Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
22 Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study Completed NCT02249676 Phase 2
23 An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica Completed NCT02865018 Phase 1, Phase 2 cetirizine
24 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
25 Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
26 Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial Recruiting NCT03863015 Phase 2 Tocilizumab 20 Mg/mL Intravenous Solution;isotonic saline
27 Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
28 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
29 THOR - Tübingen Choroideremia Gene Therapy Trial Open Label Phase 2 Clinical Trial Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1) Active, not recruiting NCT02671539 Phase 2
30 Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders: a Prospective, Multicenter, Single-blind, Randomized Controlled Clinical Trial Not yet recruiting NCT04064944 Phase 2
31 Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
32 An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Completed NCT01777412 Phase 1 Bevacizumab
33 Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Completed NCT02276963 Phase 1 Ublituximab
34 A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
35 Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
36 Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis Completed NCT00501748 Phase 1 Rituximab
37 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
38 A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders Not yet recruiting NCT04146285 Phase 1 BAT4406F
39 Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD) Withdrawn NCT03605238 Phase 1
40 A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks Withdrawn NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
41 Observational Prospective Multicentered Study Evaluating Initial Clinical Presentation of Inflammatory Optic Neuritis (ON) Associated or Not With Autoantibodies Anti- Myelin-oligodendrocyte-glycoprotein (MOG-Ab) Unknown status NCT03345537
42 Evaluation of Macular and Retinal Nerve Fiber Layer Thickness Measurements for Detection of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Optical Coherence Tomography. Unknown status NCT01024985
43 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
44 The French Multiple Sclerosis Registry Unknown status NCT02889965
45 Phase II, Randomized, Single Blind Sham Controlled Trial Investigating Scrambler Therapy for Neuropathic Pain Caused by Neuromyelitis Optica Spectrum Disorder Completed NCT03452176
46 A Pathologic-MRI Reappraisal of Patients With Atypical Idiopathic Inflammatory Demyelinating Disorders Completed NCT03121105
47 Immunologic Biomarker Profile of Cerebrospinal Fluid Completed NCT04202055
48 Optical Coherence Tomography for the Etiological Diagnosis of Inflammatory Optic Neuritis Completed NCT02573792
49 A Prospective, Observational Study On The Progression Of Clinically Isolated Syndrome (CIS) To Multiple Sclerosis Over A 2-year Period Completed NCT01112657
50 Pediatric Neuromyelitis Optica Spectrum Disorder (NMOSD) 1 Year Observational Study Recruiting NCT03766347

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

40
Brain, B Cells, Spinal Cord, T Cells, Lung, Eye, Testes

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 1161)
# Title Authors PMID Year
1
Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders. 61
31986374 2020
2
Neuromyelitis Optica Spectrum Disorder and Anti-Aquaporin 4 Channel Immunoglobulin in an Australian Pediatric Demyelination Cohort. 61
31896291 2020
3
Massive activity of cytotoxic cells during refractory Neuromyelitis Optica spectrum disorder. 61
31986375 2020
4
Lower serum interleukin-22 and interleukin-35 levels are associated with disease status in neuromyelitis optica spectrum disorders. 61
31342670 2020
5
Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. 61
31837636 2020
6
HLA-G Ins/Del polymorphism and +3142C/G SNP are not related to neuromyelitis optica spectrum disorder (NMOSD) development, disability status or anti-aquaporin 4 presence in Brazilian patients. 61
31765953 2020
7
Striking neurologic 18F-FDG PET/CT pattern in Devic's disease (neuromyelitis optica spectrum disorder). 61
31776629 2020
8
Reduced sarcolemmal aquaporin 4 expression can support the differential diagnosis of neuromyelitis optica spectrum disorders. 61
31786498 2020
9
Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study. 61
31841737 2020
10
A population-based epidemiological study of neuromyelitis optica spectrum disorder in Hungary. 61
31465603 2020
11
Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. 61
32020080 2020
12
Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. 61
31743235 2020
13
Cognitive functions in Egyptian neuromyelitis optica spectrum disorder. 61
31790906 2020
14
CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. 61
31582425 2020
15
Neuromyelitis optica spectrum disorder coexisting with ankylosing spondylitis: A case report. 61
32036261 2020
16
Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. 61
31835211 2020
17
PRES-like presentation in MOG antibody-related demyelination (MARD). 61
31982280 2020
18
MRI differences between MOG antibody disease and AQP4 NMOSD. 61
31937191 2020
19
The clinical profile of NMOSD in Australia and New Zealand. 61
32006158 2020
20
Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases. 61
31978673 2020
21
A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders. 61
31955136 2020
22
Evaluation of ethnicity as a predictor of diagnostic phenotype and prognosis in neuromyelitis optica spectrum disorder in Toronto, Canada. 61
31982662 2020
23
Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee. 61
31705563 2020
24
Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). 61
31927341 2020
25
Comparison of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. 61
31942768 2020
26
Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. 61
31715457 2020
27
Acute Presentation of Subacute Combined Degeneration Mimicking Multiple Sclerosis- Neuromyelitis Optica Spectrum Disorder. 61
31979639 2020
28
Can a diagnosis of multiple sclerosis be made without ruling out neuromyelitis optica spectrum disorder ? 61
31986427 2020
29
Decreased mRNA Expressions of CD40L in Patients with Neuromyelitis Optica Spectrum Disorder. 61
31925706 2020
30
Neuromyelitis optica spectrum disorder and active tuberculosis. 61
31900293 2020
31
Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. 61
31757816 2020
32
Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long-term relapse-free form from a large Chinese population. 61
31932912 2020
33
Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. 61
31796527 2020
34
Optic neuritis in the era of biomarkers. 61
31425702 2020
35
Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM). 61
31960250 2020
36
Sexual dysfunction in patients with neuromyelitis optica spectrum disorder. 61
31726377 2020
37
Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma. 61
31706113 2020
38
Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort. 61
31932911 2020
39
Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings. 61
31587392 2020
40
[A case of neuromyelitis optica spectrum disorder with persistent nausea and repeated syncope]. 61
31956194 2020
41
Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience. 61
31976082 2020
42
Neuromyelitis optica spectrum disorder with severe orthostatic hypotension due to hypothalamic lesions. 61
32036263 2020
43
[Prospects for Treatment of Neuromyelitis Optica Spectrum Disorder]. 61
31907333 2020
44
Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder. 61
31304648 2020
45
The differential expression of natural killer cells in NMOSD and MS. 61
31864829 2020
46
Neuromyelitis Optica Spectrum Disorder Causing Longitudinally Extending Transverse Myelitis -A Case Report. 61
31979654 2020
47
Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. 61
32010226 2020
48
Two Cases of Very-Late-Onset Neuromyelitis Optica Spectrum Disorder (NMOSD) in Patients over the Age of 80. 61
32009931 2020
49
Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder (NMOSD) patients. 61
31852443 2019
50
Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. 61
31103517 2019

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Cellular components related to Neuromyelitis Optica Spectrum Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.96 CD27 AQP4
2 basolateral plasma membrane GO:0016323 8.62 CADM1 AQP4

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....